Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus

REFERENCES

1. 1.↵
   1. Isenberg DA,
   2. Manson JJ,
   3. Ehrenstein MR,
   4. Rahman A

   . Fifty years of anti-ds DNA antibodies: are we approaching journey’s end? Rheumatology 2007;46:1052–6.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Gladman DD,
   2. Urowitz MB,
   3. Keystone EC

   . Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med 1979;66:210–5.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Rothfield NF,
   2. Stollar BD

   . The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 1967;46:1785–94.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Winfield JB,
   2. Faiferman I,
   3. Koffler D

   . Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest 1977;59:90–6.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Puritz EM,
   2. Yount WJ,
   3. Newell M,
   4. Utsinger PD

   . Immunoglobulin classes and IgG subclasses of human antinuclear antibodies. A correlation of complement fixation and the nephritis of systemic lupus erythematosus. Clin Immunol Immunopathol 1973;2:98–113.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Villalta D,
   2. Romelli PB,
   3. Savina C,
   4. Bizzaro N,
   5. Tozzoli R,
   6. Tonutti E,
   7. et al.

   Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus 2003;12:31–6.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Förger F,
   2. Matthias T,
   3. Oppermann M,
   4. Becker H,
   5. Helmke K

   . Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004;13:36–44.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Krippner H,
   2. Merle S,
   3. Jörgens K,
   4. Pirlet K

   . Antibodies to dsDNA and ssDNA in the immunoglobulin classes IgG and IgM: prognostic value in the course of SLE. Z Rheumatol 1984;43:265–71.

   OpenUrlPubMed
9. 9.↵
   1. Kessel A,
   2. Rosner I,
   3. Halasz K,
   4. Grushko G,
   5. Shoenfeld Y,
   6. Paran D,
   7. et al.

   Antibody clustering helps refine lupus prognosis. Semin Arthritis Rheum 2009;39:66–70.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Bijl M,
    2. Dijstelbloem HM,
    3. Oost WW,
    4. Bootsma H,
    5. Derksen RH,
    6. Aten J,
    7. et al.

    IgG subclass distribution of autoantibodies differs between renal and extra-renal relapses in patients with systemic lupus erythematosus. Rheumatology 2002;41:62–7.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Hahn BH

    . Antibodies to DNA. N Engl J Med 1998;338:1359–68.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Suleiman S,
    2. Kamaliah D,
    3. Nadeem A,
    4. Naing NN,
    5. Che Maraina CH

    . Anti-nucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus. Int J Rheum Dis 2009;12:100–6.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Min DJ,
    2. Kim SJ,
    3. Park SH,
    4. Seo YI,
    5. Kang HJ,
    6. Kim WU,
    7. et al.

    Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol 2002;20:13–8.

    OpenUrlPubMed
14. 14.↵
    1. Manson JJ,
    2. Ma A,
    3. Rogers P,
    4. Mason LJ,
    5. Berden JH,
    6. van der Vlag J,
    7. et al.

    Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther 2009;11:R154.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Kiss E,
    2. Lakos G,
    3. Szegedi G,
    4. Poor G,
    5. Szodoray P

    . Anti-nuscleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity 2009;42:393–8.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Gutiérrez-Adrianzén OA,
    2. Koutouzov S,
    3. Mota RM,
    4. das Chagas Medeiros MM,
    5. Bach JF,
    6. de Holanda Campos H

    . Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol 2006;33:1538–44.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Gómez-Puerta JA,
    2. Burlingame RW,
    3. Cervera R

    . Anti-chromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmunity Rev 2008;7:606–11.

    OpenUrlCrossRef
18. 18.↵
    1. Ghillani-Dalbin P,
    2. Amoura Z,
    3. Cacoub P,
    4. Charuel JL,
    5. Diemert MC,
    6. Piette JC,
    7. et al.

    Testing for anti-nucleosome antibodies in daily practice: a monocentric evaluation in 1696 patients. Lupus 2003;12:833–7.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Bizzaro N,
    2. Villalta D,
    3. Giavarina D,
    4. Tozzoli R

    . Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev 2012;12:97–106.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Heidenreich U,
    2. Mayer G,
    3. Herold M,
    4. Klotz W,
    5. Stempfl Al-Jazrawi K,
    6. Lhotta K

    . Sensitivity and specificity of autoantibody tests in the differential diagnosis of lupus nephritis. Lupus 2009;18:1276–80.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Urowitz MB,
    2. Gladman DD

    . Contributions of observational cohort studies in systemic lupus erythematosus: the University of Toronto lupus clinic experience. Rheum Dis Clin North Am 2005;31:211–21.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Cheung YH,
    2. Landolt-Marticorena C,
    3. Lajoie G,
    4. Wither JE

    . The lupus phenotype in B6.NZBc1 congenic mice reflects interactions between multiple susceptibility loci and a suppressor locus. Genes Immun 2011;12:251–62.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Li T,
    2. Prokopec SD,
    3. Morrison S,
    4. Lou W,
    5. Reich H,
    6. Gladman D,
    7. et al.

    Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. Rheumatology 2014 Sep 5 (E-pub ahead of print).
24. 24.↵
    1. Yager TD,
    2. McMurray CT,
    3. Van Holde KE

    . Salt-induced release of DNA from nucleosome core particles. Biochemistry 1989;28:2271–81.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Steiman AJ,
    2. Gladman DD,
    3. Ibañez D,
    4. Urowitz MB

    . Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010;37:1822–7.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Steiman AJ,
    2. Gladman DD,
    3. Ibañez D,
    4. Urowitz MB

    . Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res 2012;64:511–8.

    OpenUrlCrossRef
27. 27.↵
    1. Villalta D,
    2. Bizzaro N,
    3. Bassi N,
    4. Zen M,
    5. Gatto M,
    6. Ghirardello A,
    7. et al.

    Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PloS One 2013;8: e71458.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Werwitzke S,
    2. Trick D,
    3. Kamino K,
    4. Matthias T,
    5. Kniesch K,
    6. Schlegelberger B,
    7. et al.

    Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse. Arthritis Rheum 2005;52:3629–38.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Muller S,
    2. Dieker J,
    3. Tincani A,
    4. Meroni PL

    . Pathogenic anti-nucleosome antibodies. Lupus 2008;17:431–6.

    OpenUrlAbstract/FREE Full Text
30. 30.↵
    1. van der Vlag J,
    2. Berden JH

    . Lupus nephritis: role of antinucleosome autoantibodies. Semin Nephrol 2011;31:376–89.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Dieker JW,
    2. van der Vlag J,
    3. Berden JH

    . Triggers for anti-chromatin autoantibody production in SLE. Lupus 2002;11:856–64.

    OpenUrlAbstract/FREE Full Text
32. 32.↵
    1. Pradhan VD,
    2. Patwardhan MM,
    3. Ghosh K

    . Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies. Indian J Dermatol Venereol Leprol 2010;76:145–9.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Andreoli L,
    2. Pregnolato F,
    3. Burlingame RW,
    4. Allegri F,
    5. Rizzini S,
    6. Fanelli V,
    7. et al.

    Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? J Autoimmun 2008;30:51–7.

    OpenUrlCrossRefPubMed
34. 34.↵
    1. Ng KP,
    2. Manson JJ,
    3. Rahman A,
    4. Isenberg DA

    . Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006;55:900–4.

    OpenUrlCrossRefPubMed
35. 35.↵
    1. ter Borg EJ,
    2. Horst G,
    3. Hummel E,
    4. Limburg PC,
    5. Kallenberg CG

    . Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation. Clin Immunol Immunopathol 1991;59:117–28.

    OpenUrlCrossRefPubMed